Search company, investor...

Stage

Other Investors | Alive

About Cenes

The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

Headquarters Location

PAION UK (formerly CeNeS) Chivers Way, Histon

CB24 9ZR,

United Kingdom

Loading...

Loading...

Cenes Patents

Cenes has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/5/2007

5/5/2009

Benzodiazepines, Lactams, Fluoroarenes, Anxiolytics, Muscle relaxants

Grant

Application Date

1/5/2007

Grant Date

5/5/2009

Title

Related Topics

Benzodiazepines, Lactams, Fluoroarenes, Anxiolytics, Muscle relaxants

Status

Grant

Latest Cenes News

Billy Joel -- ’Scenes From An Italian Restaurant’

Feb 18, 2015

Go to permalink Traffic sucks, so why not start your morning off with some music? You provide the toast and we'll provide the jams. I usually start my day off with a bottle of red and a bottle of white. But not rose because that's gross.

Cenes Frequently Asked Questions (FAQ)

  • What is Cenes's latest funding round?

    Cenes's latest funding round is Other Investors.

  • Who are the investors of Cenes?

    Investors of Cenes include Alta Berkeley.

  • Who are Cenes's competitors?

    Competitors of Cenes include Evotec SE, Neurelis, Selecta Biosciences, Somaxon Pharmaceuticals, CNS Therapeutics and 7 more.

Loading...

Compare Cenes to Competitors

I
Ikano Therapeutics

Ikano Therapeutics operates as a specialty pharmaceutical company. It develops nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system. It develops products to treat acute and moderate-to-severe pain. The company was founded in 1998 and is based in Saddle Brook, New Jersey.

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Neurelis Logo
Neurelis

Neurelis focuses on life-changing therapeutics in the neurological conditions sector. The company's main offerings include the development of treatments designed to help individuals with neurological conditions gain better control over their health. It was founded in 2007 and is based in San Diego, California.

R
Richwood Pharmaceutical

Richwood develops drugs for disorders of the central nervous system, particularly hyperactivity in children.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

N
Nano-Mite Technologies

Nano-Mite Technologies is engaged in R&D to control obesity using nanotechnology that alters the body's metabolic rate and increase the cell's ability to convert sugar to energy. Per the company, Nano-Mite's technnology could lead to futures in the treatment of traumatic central nervous system damage and neurodegenerative disorders.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.